Cargando…

A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs

Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Zhang, Lin, Xu, Chu, Shen, Ying-Ying, Lin, Yu-Hui, Zhang, Yu, Wu, Hai-Yin, Chang, Lei, Zhang, Ying-Dong, Chen, Rong, Zhang, Zheng-Ping, Luo, Chun-Xia, Li, Fei, Zhu, Dong-Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058733/
https://www.ncbi.nlm.nih.gov/pubmed/33897893
http://dx.doi.org/10.7150/thno.58364
_version_ 1783681069850034176
author Li, Jun
Zhang, Lin
Xu, Chu
Shen, Ying-Ying
Lin, Yu-Hui
Zhang, Yu
Wu, Hai-Yin
Chang, Lei
Zhang, Ying-Dong
Chen, Rong
Zhang, Zheng-Ping
Luo, Chun-Xia
Li, Fei
Zhu, Dong-Ya
author_facet Li, Jun
Zhang, Lin
Xu, Chu
Shen, Ying-Ying
Lin, Yu-Hui
Zhang, Yu
Wu, Hai-Yin
Chang, Lei
Zhang, Ying-Dong
Chen, Rong
Zhang, Zheng-Ping
Luo, Chun-Xia
Li, Fei
Zhu, Dong-Ya
author_sort Li, Jun
collection PubMed
description Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric oxide synthase (nNOS), causes analgesic tolerance, mainly due to GABAergic disinhibition. The aim of this study is to explore the possibility of preventing analgesic tolerance through co-targeting NMDAR downstream signaling and γ-aminobutyric acid type A receptors (GABA(A)Rs). Methods: Mechanical/thermal hyperalgesia were quantified to assess analgesic effects. Miniature postsynaptic currents were tested by patch-clamp recording to evaluate synaptic transmission in the SDH. GABA-evoked currents were tested on HEK293 cells expressing different subtypes of recombinant GABA(A)Rs to assess the selectivity of (+)-borneol and ZL006-05. The expression of α2 and α3 subunits of GABA(A)Rs and BDNF, and nNOS-PSD-95 complex levels were analyzed by western blotting and coimmunoprecipitation respectively. Open field test, rotarod test and Morris water maze task were conducted to evaluate the side-effect of ZL006-05. Results: (+)-Borneol selectively potentiated α2- and α3-containing GABA(A)Rs and prevented the disinhibition of laminae I excitatory neurons in the SDH and analgesic tolerance caused by chronic use of ZL006, a nNOS-PSD-95 blocker. A dual-target compound ZL006-05 produced by linking ZL006 and (+)-borneol through an ester bond blocked nNOS-PSD-95 interaction and potentiated α2-containing GABA(A)R selectively. Chronic use of ZL006-05 did not produce analgesic tolerance and unwanted side effects. Conclusion: By targeting nNOS-PSD-95 interaction and α2-containing GABA(A)R simultaneously, chronic use of ZL006-05 can avoid analgesic tolerance and unwanted side effects. Therefore, we offer a novel candidate drug without analgesic tolerance for treating neuropathic pain.
format Online
Article
Text
id pubmed-8058733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-80587332021-04-23 A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs Li, Jun Zhang, Lin Xu, Chu Shen, Ying-Ying Lin, Yu-Hui Zhang, Yu Wu, Hai-Yin Chang, Lei Zhang, Ying-Dong Chen, Rong Zhang, Zheng-Ping Luo, Chun-Xia Li, Fei Zhu, Dong-Ya Theranostics Research Paper Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric oxide synthase (nNOS), causes analgesic tolerance, mainly due to GABAergic disinhibition. The aim of this study is to explore the possibility of preventing analgesic tolerance through co-targeting NMDAR downstream signaling and γ-aminobutyric acid type A receptors (GABA(A)Rs). Methods: Mechanical/thermal hyperalgesia were quantified to assess analgesic effects. Miniature postsynaptic currents were tested by patch-clamp recording to evaluate synaptic transmission in the SDH. GABA-evoked currents were tested on HEK293 cells expressing different subtypes of recombinant GABA(A)Rs to assess the selectivity of (+)-borneol and ZL006-05. The expression of α2 and α3 subunits of GABA(A)Rs and BDNF, and nNOS-PSD-95 complex levels were analyzed by western blotting and coimmunoprecipitation respectively. Open field test, rotarod test and Morris water maze task were conducted to evaluate the side-effect of ZL006-05. Results: (+)-Borneol selectively potentiated α2- and α3-containing GABA(A)Rs and prevented the disinhibition of laminae I excitatory neurons in the SDH and analgesic tolerance caused by chronic use of ZL006, a nNOS-PSD-95 blocker. A dual-target compound ZL006-05 produced by linking ZL006 and (+)-borneol through an ester bond blocked nNOS-PSD-95 interaction and potentiated α2-containing GABA(A)R selectively. Chronic use of ZL006-05 did not produce analgesic tolerance and unwanted side effects. Conclusion: By targeting nNOS-PSD-95 interaction and α2-containing GABA(A)R simultaneously, chronic use of ZL006-05 can avoid analgesic tolerance and unwanted side effects. Therefore, we offer a novel candidate drug without analgesic tolerance for treating neuropathic pain. Ivyspring International Publisher 2021-04-03 /pmc/articles/PMC8058733/ /pubmed/33897893 http://dx.doi.org/10.7150/thno.58364 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Li, Jun
Zhang, Lin
Xu, Chu
Shen, Ying-Ying
Lin, Yu-Hui
Zhang, Yu
Wu, Hai-Yin
Chang, Lei
Zhang, Ying-Dong
Chen, Rong
Zhang, Zheng-Ping
Luo, Chun-Xia
Li, Fei
Zhu, Dong-Ya
A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title_full A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title_fullStr A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title_full_unstemmed A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title_short A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
title_sort pain killer without analgesic tolerance designed by co-targeting psd-95-nnos interaction and α2-containning gaba(a)rs
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058733/
https://www.ncbi.nlm.nih.gov/pubmed/33897893
http://dx.doi.org/10.7150/thno.58364
work_keys_str_mv AT lijun apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhanglin apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT xuchu apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT shenyingying apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT linyuhui apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangyu apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT wuhaiyin apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT changlei apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangyingdong apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT chenrong apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangzhengping apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT luochunxia apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT lifei apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhudongya apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT lijun painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhanglin painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT xuchu painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT shenyingying painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT linyuhui painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangyu painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT wuhaiyin painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT changlei painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangyingdong painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT chenrong painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhangzhengping painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT luochunxia painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT lifei painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars
AT zhudongya painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars